PISCIVAC Irido Si

Category Vaccine

Vaccine type

Inactivated water-based vaccine for intramuscular and intraperitoneal injections

Target Diseases

Iridoviral disease caused by infectious spleen and kidney necrosis virus (ISKNV)
Streptococcosis caused by Streptococcus iniae

Target Species

Asian seabass or barramundi

Key Features

Rapid protection within 3 dpv against ISKNV and S. iniae in Asian seabass
Long duration of protection against iridoviral disease and streptococcosis for at least 2 mpv and 11 mpv, respectively

Efficacy

Laboratory test Trial I

Pathogens	DPV	RPS
ISKNV	21	76
S. iniae	32	78

Laboratory test Trial II

Pathogens	DPV	RPS
ISKNV	3	89
	7	85
	14	79
S. iniae	3	89
	7	97
	14	100

Laboratory test Trial III

Pathogens	DPV	RPS
ISKNV	28	90
ISKNV	74	75
S. iniae	102	90
S. iniae	348	88

DPV: days post-vaccination

RPS: relative percent survival

PISCIVAC Irido Si

PISCIVAC Irido Si - Image 2

PISCIVAC Irido Si - Image 3

PISCIVAC Irido Si - Image 4

PISCIVAC Irido Si - Image 5

Vaccines available in the market

Vaccines for Streptococcus iniae bacteria infection and Iridovirus infection are sold separately.
Oil-based vaccine which the fish will take longer to dissipate.

Solutions from Kyoritsu

In order to tackle the 2 most common infections for Barramundi, a two-in-one vaccine has been developed in Piscivac Irido Si.
Having a two-in-one vaccine is more cost effective and more productive as the task of vaccinating the fish is made easier.
Kyoritus’s water-base vaccine can be easily absorbed by the fish.